

Digestive Diseases Research Seminar
*Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases*

Exploring similarities between nonalcoholic and alcohol associated steatohepatitis as therapeutic opportunity

Bubu Banini, MD, PhD

Assistant Professor of Medicine; Translational Research Director of the
Metabolic Health and Weight Loss Program, Digestive Diseases
Department of Medicine, Yale School of Medicine

Tuesday, March 15, 2022
5:00 - 6:00 pm

<https://zoom.us/j/92025519317?pwd=bWJxcTRReUl5TWxSb1Z5b1N0YWMrUT09&from=addon>

Host: Wajahat Mehal, PhD, MD

Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29439) to 203-442-9435.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Nonalcoholic steatohepatitis and alcohol associated liver disease are leading causes of liver disease and mortality worldwide. Currently, the mainstay of treatment for both conditions is lifestyle modification. There is a dire unmet need for pharmacotherapy to treat these conditions. **Objectives:** Describe the prevalence and pathogenesis of nonalcoholic steatohepatitis (NASH) and alcohol associated steatohepatitis (ASH). Describe the disease mediators and pathways common to nonalcoholic and alcohol associated liver disease that can be harnessed in developing pharmacotherapy. Discuss the preclinical data supporting digoxin in ASH and NASH and describe the currently ongoing clinical trial of digoxin in patients with alcohol associated hepatitis. **Faculty Disclosures:** Faculty/planners for this educational activity have no relevant financial relationship(s) with ineligible companies to disclose. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**